echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Natural Products News > CCR: inflammation and obesity in collusion, prostate cancer patients at risk

    CCR: inflammation and obesity in collusion, prostate cancer patients at risk

    • Last Update: 2018-07-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    July 23, 2018 / bioin / - known inflammation and immune cell infiltration are new features of cancer It is worth noting that high fat diet (HFD) can lead to obesity and chronic inflammation, and studies in mice have shown that HFD is related to the progress of prostate cancer and the survival rate of patients In human studies, it seems that inflammation and immune cells are also linked to prostate cancer Image source: Osaka University although researchers have known how HFD causes the increase of pro-inflammatory cytokines in serum, they do not know whether the tumor progression is due to the role of these cytokines In a new study published in clinical cancer research, researchers from Osaka University have successfully revealed the mechanism of prostate cancer associated with inflammation and immune response "We injected a genetically engineered mouse model of spontaneous prostate cancer with HFD and the anti-inflammatory drug celecoxib." Takuji Hayashi, lead author of the study, said "We monitored tumor growth by tumor weighing and Ki67 staining at 22 weeks, and detected immune cells in tumor by flow cytometry Through further research, we have found cytokines related to tumor growth The researchers found that HFD accelerated tumor growth, increased the proportion of myeloid derived inhibitory cells (MDSCs) and the ratio of M2 macrophages to MI macrophages in mice MDSCs control the immune response and tissue repair of normal individuals, and can proliferate rapidly when inflammation, infection and cancer occur Celecoxib can inhibit the growth of tumor and decrease the ratio of local MDSCs to m2 / MI macrophages in HFD fed mice Injection of IL-6 receptor specific antibody can inhibit tumor growth and reduce the proportion of local MDSCs and PSTAT3 positive cells In response to cytokines and growth factors, STAT3 will be phosphorylated into PSTAT3 and enter the nucleus, which can play a role as a gene transcription activator Researchers have found that the proportion of tumor infiltrating CD11b positive cells in prostate cancer tissue samples from obese patients is also significantly higher than that of non obese prostate cancer patients "Combined with this information, our results suggest that HFD may also induce prostate cancer growth through IL6 signaling in these patients." Kazutoshi Fujita, the study's co-author, said "Anti inflammatory drugs like celecoxib may have a clinical effect on obese prostate cancer patients In addition, changing eating habits may help prevent obesity and help treat prostate cancer " Reference: takuji Hayashi et al High fat diet induced infection accelerates promote cancer growth via IL6 signaling, clinical cancer research (2018) Doi: 10.1158/1078-0432.ccr-18-0106
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.